How to identify the authenticity of Giritinib (Segatan) and how to prevent counterfeiting

Gilteritinib (Gilteritinib) is an oral targeted drug used to treat FLT3 mutation-positive acute myeloid leukemia (AML). Due to its high price and large market demand, patients must pay attention to the authenticity and source of the drug when purchasing to ensure the safety of the drug. The first way to identify the authenticity of giritinib is to choose formal channels for purchase, including hospital pharmacies approved by the State Food and Drug Administration, authorized drug distribution centers, and formal overseas drug import channels. By purchasing through formal channels, you can not only ensure the quality of the medicine, but also obtain complete drug instructions and usage guidance.

Secondly, it can be identified by the drug packaging and appearance. Genuine giritinib packaging is usually clearly printed, with standardized fonts, bottle labels, production batch numbers, expiration dates, and manufacturer information, and is accompanied by anti-counterfeiting logos or QR codes. When patients or family members receive medicines, they should carefully check whether the outer packaging is complete, whether the seal is intact, and whether the instructions and outer box information are consistent. Drugs with abnormal packaging, blurred printing, or lack of batch numbers or QR codes should be immediately vigilant and avoided.

Third, use anti-counterfeiting technology for verification. Some regular drugs will provide QR codes, anti-counterfeiting codes or scratch cards. You can check the authenticity and production information of the drugs by scanning the codes or calling the drug service hotline. When purchasing giritinib, patients can use their mobile phones to scan the QR code or log in to the manufacturer's official website to verify the source of the drug and confirm whether the production batch number and expiration date information are consistent with the drug itself. If the query information is inconsistent with the drug, you should immediately stop using it and report it to the drug regulatory department.

Finally, patients should make a comprehensive judgment based on drug efficacy and clinical response when using giritinib. After taking genuine drugs, improvement in hematological indicators or disease remission can usually be observed under the guidance of a doctor. If there are abnormal drug effects or side effects that are seriously inconsistent with the description in the instructions, you should stop taking the drug in time and consult a doctor. At the same time, keep the drug packaging and purchase receipt to facilitate tracing the source. In short, choosing formal channels to purchase, checking packaging information, anti-counterfeiting verification and observing drug efficacy are key measures to identify the authenticity of giritinib, which will help ensure the safety and efficacy of treatment.

Reference materials:https://www.drugs.com/